CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel
Commercial payers pay $523 on average nationally for this procedure.
CPT code 81410 describes a genomic sequencing panel performed by a laboratory analyst to evaluate a patient specimen for pathogenic or likely pathogenic genetic sequences across at least nine genes associated with heritable thoracic aortic disease and aortic dysfunction or dilation; this is a molecular diagnostic service typically performed on extracted DNA in a clinical molecular laboratory and reported as a targeted multi-gene panel for hereditary aortopathy evaluation.
Customize your policy alerts
Sign up for cpt 81410 policy alerts
Get alerted when payer policies referencing 81410 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial national rates for CPT 81410 cluster around BUCA’s average commercial rate of $523, which serves as a useful cross-payer anchor. Blue Cross Blue Shield shows the highest dispersion between the 75th and 25th percentiles (range $180, from $432 to $624), indicating broader variability in negotiated commercial payments, while Aetna and UnitedHealth Group display narrower interquartile spreads: Aetna’s IQR is $184 (from $229 to $413) and UnitedHealth Group’s IQR is $287 (from $212 to $504). Cigna’s IQR is $379 (from $258 to $656) and BUCA’s IQR is $248 (from $347 to $581).
In absolute terms, Blue Cross Blue Shield and Cigna exhibit the widest variability, suggesting more heterogeneous contracting outcomes across markets. Aetna and BUCA sit closer to the middle of the distribution, and UnitedHealth Group’s statistics reflect a tighter lower quartile but a higher upper quartile, producing an intermediate spread. These differences highlight payer-specific dispersion without implying suitability for any single contract strategy.